ST Pharm Continues Winning New Orders, Says "Opportunities for Sustained Growth Are Being Created"
Predicted impact: Low
New orders mentioned without size; growth already reported in Q3.
ST Pharm에스티팜
237690 · KOSDAQ · ₩237690 · 에스티팜
₩72,500▼ ₩1,500 (2.03%)End-of-day · Oct 30, 2026 · End-of-day prices.
"Orders up and sales jumped, but"... Why ST Pharm's target price was cut
Predicted impact: Low
Revenue up 19% and profit growth; target cut is modest and results were mostly as expected.
ST Pharm Q3 revenue ₩97.6B, up 19% year on year
Predicted impact: Low
Dong-A ST and ST Pharm Both Grow in Q3, Sales and Operating Profit Rise Together
Predicted impact: Low
Routine Q3 growth announcement; same results already covered in recent preliminary earnings.
Dong-A ST and ST Pharm Post Revenue and Profit Growth in Q3 (Japanese: 東亜STとST Pharm 第3四半期で増収増益)
Predicted impact: Low
Q3 growth of 19.1% revenue and 6.6% operating profit, small relative to firm; already reported.
ST Pharm revenue up 19.1% as oligo commercialization orders expand
Predicted impact: Low
Revenue up 19.1% with modest profit growth; already reported.
ST Pharm Q3 Operating Profit at ₩15.7B, Up 6.6% Year-on-Year
Predicted impact: Low
Q3 operating profit up 6.6% year on year; modest change, small relative to revenue.
[Today's IR] Dong-A Pharmaceutical, Hanmi Pharm, ST Pharm and Others
Predicted impact: Low
ST Pharm aims to expand RNA orders with Roche support
Predicted impact: Low
Same Roche-backed RNA order ambition already reported; no new size given.
Roche to provide production facilities and transfer technology, ST Pharm eyes large RNA order
Predicted impact: Medium
Potential large RNA order sought; size not disclosed, so only meaningful but uncertain.
Also known as: ST Pharm / 에스티팜 / 237690 / KRX:237690
Source: KRX statistical information